Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Launched by ANAPTYSBIO, INC. · Apr 25, 2022
Trial Information
Current as of July 06, 2025
Completed
Keywords
ClinConnect Summary
This study will also characterize the pharmacokinetic (PK) profile of imsidolimab and explore the immunogenicity of imsidolimab in subjects with GPP.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • -Subject has a BSA affected with pustules (excluding palms and soles) ≥ 5%, a GPPPGA score ≥ 3 (moderate severity), and a PRS score ≥ 3 (moderate severity) at Day 1
- Exclusion Criteria:
- • Subject has other form of psoriasis excluding psoriasis vulgaris
- • Subject flare is so severe that patient's life is at risk
About Anaptysbio, Inc.
Anaptysbio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious diseases. Leveraging its proprietary GigaMAB™ platform, Anaptysbio specializes in creating differentiated antibody products that target key immune pathways. The company's robust pipeline includes candidates aimed at addressing unmet medical needs across various therapeutic areas, including immunology and oncology. With a commitment to advancing science and improving patient outcomes, Anaptysbio is dedicated to translating groundbreaking research into effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Largo, Florida, United States
Louisville, Kentucky, United States
Ann Arbor, Michigan, United States
Dallas, Texas, United States
Springville, Utah, United States
Melbourne, , Australia
Sydney, , Australia
Batumi, , Georgia
Tbilisi, , Georgia
Tbilisi, , Georgia
Tbilisi, , Georgia
Tbilisi, , Georgia
Bensheim, , Germany
Bonn, , Germany
Hanau, , Germany
Würzburg, , Germany
Pusan, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Cheras, , Malaysia
Johor Bahru, , Malaysia
Kota Bharu, , Malaysia
Kuala Lumpur, , Malaysia
Muar, , Malaysia
Putrajaya, , Malaysia
Casablanca, , Morocco
Casablanca, , Morocco
Oujda, , Morocco
Kraków, , Poland
Ossy, , Poland
Rzeszów, , Poland
Wrocław, , Poland
łódź, , Poland
Bucuresti, , Romania
Cluj Napoca, , Romania
Iaşi, , Romania
Svidník, , Slovakia
Barcelona, , Spain
Las Palmas De Gran Canaria, , Spain
Madrid, , Spain
Madrid, , Spain
Valencia, , Spain
Kaohsiung, , Taiwan
Taipei, , Taiwan
Taipei, , Taiwan
Taipei, , Taiwan
Bangkok, , Thailand
Chiang Mai, , Thailand
Khon Kaen, , Thailand
Pathum Thani, , Thailand
Sfax, , Tunisia
Sousse, , Tunisia
Tunis, , Tunisia
Ankara, , Turkey
Antalya, , Turkey
Istanbul, , Turkey
Istanbul, , Turkey
Istanbul, , Turkey
Nilufer, , Turkey
Patients applied
Trial Officials
Bruce Randazzo, MD
Study Director
AnaptysBio, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials